Olanzapine (Zyprexa) in Pregnancy
Olanzapine can be used during pregnancy when the potential benefit justifies the potential risk to the fetus, with the most recent and highest quality evidence showing no increased risk of major malformations. 1
Evidence for Safety
The strongest available evidence comes from a 2023 prospective registry study that found zero major malformations among 49 infants exposed to olanzapine in the first trimester (absolute risk 0.00%, 95% CI 0.00-7.25%), compared to 1.64% in unexposed controls 2. This prospective data is particularly reassuring, though the sample size means modest effects cannot be ruled out.
Additional safety data from Eli Lilly's global surveillance database of 610 prospectively identified pregnancies showed:
- 66% normal births
- 9.8% premature births
- 8% perinatal conditions
- Frequencies consistent with general population rates 3
Clinical Decision-Making Algorithm
When to Continue Olanzapine:
- Patient has schizophrenia or bipolar disorder requiring ongoing treatment
- Previous relapse when medication discontinued
- Symptoms significantly impair daily functioning
- Risk of untreated psychiatric illness outweighs theoretical fetal risks
Key Consideration: Untreated schizophrenia during pregnancy carries documented risks including increased spontaneous abortion and preterm birth 4. Relapse during pregnancy exposes both mother and fetus to high risk 5.
Dosing Approach
- Continue current effective dose if patient is stable
- Use the lowest effective dose that maintains symptom control
- Consider dose adjustments based on clinical response, not arbitrary reduction for pregnancy
Required Monitoring
Maternal monitoring:
- Fasting blood glucose at baseline and periodically (olanzapine increases hyperglycemia risk) 1
- Lipid profiles regularly 1
- Blood pressure checks for preeclampsia
- Weight gain monitoring 1
- Complete blood count if history of low WBC 1
Fetal monitoring:
- Regular fetal growth assessments
- Watch for oligohydramnios (reported in case series) 6
Neonatal monitoring:
- Observe for poor neonatal adaptation
- Monitor for sedation, irritability, feeding difficulties
Breastfeeding Considerations
Breastfeeding is not recommended per FDA labeling 1, though olanzapine is excreted in breast milk in small amounts. One case report showed very low infant plasma concentrations without adverse effects 7. The global surveillance data reported adverse events in only 17.7% of 102 breastfeeding cases, most commonly somnolence (3.9%), irritability (2%), and tremor (2%) 3.
If breastfeeding is chosen after shared decision-making:
- Monitor infant closely for sedation, poor feeding, and developmental milestones
- Ensure appropriate weight gain
Critical Caveats
Do not confuse this with stimulant use in pregnancy - the provided guidelines 4 extensively discuss ADHD medications, which are irrelevant to olanzapine use.
Metabolic risks remain during pregnancy: Olanzapine carries significant risks for weight gain, dyslipidemia, and hyperglycemia that require aggressive monitoring throughout pregnancy 1.
Document shared decision-making: The FDA label explicitly states use should occur "only if the potential benefit justifies the potential risk" 1, requiring thorough discussion of risks and benefits with the patient.